



Effective Date: 03/01/2012
Last P&T Approval/Version: 01/26/2022
Next Review Due By: 01/2023
Policy Number: C4708-A

Omega-3 Fatty Acids

PRODUCTS AFFECTED

Lovaza (omega-3-acid ethyl esters), Luvira (omega-3-acid ethyl esters), Triklos (omega-3-acidethyl esters), Vascazen (icosapent ethyl), Omega-3-acid Ethyl Esters (generic) capsules, Omega-3-acid Ethyl Esters Cap 1 GM, Vascepa (icosapent ethyl) capsule, icosapent ethyl (generic) capsules

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes.

Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive

DIAGNOSIS:

Cardiovascular risk reduction with mild hypertriglyceridemia and Hypertriglyceridemia

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review

A. HYPERTRIGLYCERIDEMIA:

1. The member has, or did have prior to the start of a triglyceride lowering drug, a triglyceride level greater than or equal to 500 mg/dL

Drug and Biologic Coverage Criteria

AND

2. Prescriber attests LDL-C levels have been evaluated and are being treated appropriately
- AND
3. Documentation member has experienced a failure of or an intolerance (i.e., sensitivity, drug allergy, or adverse effect) to treatment with at least two formulary statins (e.g., simvastatin, lovastatin)
- AND
4. Prescriber attests that appropriate lifestyle modifications have been implemented, including an appropriate diet that will continue during treatment, supported by documentation of counseling in chart notes: dietary management of mild-to-moderate hypertriglyceridemia should focus on "eating less" with a goal of weight loss, and also on reduction of carbohydrates, especially high glycemic and high fructose foods, aerobic exercise, and a diet rich in fruits and vegetables

B. CARDIOVASCULAR RISK REDUCTION WITH MILD HYPERTRIGLYCERIDEMIA:

1. Documentation of baseline elevated triglyceride (TG) levels (≥ 150 mg/dL)
- AND
2. Clinical documentation of a therapeutic failure on, intolerance to, or contraindication to high-intensity statin therapy met by ONE (1) of the following:
 - (a) Adherent* on a maximally tolerated high-intensity statin therapy (daily dose of atorvastatin 40-80 mg or rosuvastatin 20 to 40 mg) AND Inability to achieve and maintain a triglyceride level < 150 mg/dL, with a combination of medications, diet, and exercise

*NOTE: Adherence is defined as at least 85% of the time as confirmed by claim history for at least 180 days OR attestation from the prescriber.

OR

 - (b) Member has ANY of the following contraindication(s) to statin therapy [ONE]: (i) Hypersensitivity to statins or any component of the product, Active liver disease or CK levels (defined as > 10 times the Upper Limit of Normal [ULN]), Unexplained persistent elevation of hepatic transaminases [greater than 3 times the upper limit of normal (ULN) occurring on 2 or more occasions], Women who are pregnant or may become pregnant or Breastfeeding

*NOTE: Laboratory tests showing evidence of muscle inflammation, alterations of liver function tests from baseline and/or liver damage required.

AND
 3. Prescriber attests that appropriate lifestyle modifications have been implemented, including an appropriate diet that will continue during treatment, supported by documentation of counseling in chart notes: dietary management of mild-to-moderate hypertriglyceridemia should focus on "eating less" with a goal of weight loss, and also on reduction of carbohydrates, especially high glycemic and high fructose foods, aerobic exercise, and a diet rich in fruits and vegetables
- AND
4. Documentation of ONE of the following: (a) OR (b)
 - (a) Patient is ≥ 45 years AND
 - (i) Documented CAD (≥ 1 of the following primary criteria must be satisfied): Documented multivessel CAD ($\geq 50\%$ stenosis in ≥ 2 major epicardial coronary arteries, with or without antecedent revascularization) OR Documented prior MI OR Hospitalization for high-risk NSTEMI-ACS (with objective evidence of ischemia: ST-segment deviation or biomarker positivity)

OR

 - (ii) Documented cerebrovascular or carotid disease (1 of the following primary criteria must be satisfied): Documented prior ischemic stroke OR Symptomatic carotid artery disease with $\geq 50\%$ carotid arterial stenosis OR Asymptomatic carotid artery disease with $\geq 70\%$ carotid arterial stenosis per angiography or duplex ultrasound OR History of carotid revascularization (catheter-based or surgical)

OR

 - (iii) Documented PAD (≥ 1 of the following primary criteria must be satisfied): ABI < 0.9 with symptoms of intermittent claudication OR History of aortoiliac or peripheral arterial intervention (catheter-based or surgical)
- OR

Drug and Biologic Coverage Criteria

(b) Diabetes mellitus (type 1 or type 2) requiring treatment with medication AND Men and women age ≥ 50 years AND One of the following at Visit 1 (additional risk factor for CVD): (i) Men ≥ 55 years of age and women ≥ 65 years of age OR (ii) Cigarette smoker or stopped smoking within 3 months OR (iii) HTN (BP ≥ 140 mm Hg systolic OR ≥ 90 mm Hg diastolic) or on antihypertensive medication OR (iv) HDL-C ≤ 40 mg/dL for men or ≤ 50 mg/dL for women OR (v) hsCRP > 3.00 mg/L (0.3 mg/dL) OR (vi) Renal dysfunction: CrCl > 30 and < 60 mL/min OR (vii) Retinopathy, defined as any of the following: nonproliferative retinopathy, preproliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease, or a history of photocoagulation OR (viii) Micro- or macroalbuminuria.

CONTINUATION OF THERAPY:

A. HYPERTRIGLYCERIDEMIA:

1. Documentation that member's condition has not progressed or worsened on therapy AND
2. Adherence to therapy at least 85% of the time as verified by Prescriber and member's medication fill history (review Rx history for compliance) AND
3. Triglyceride level is within the normal limits or has dropped at least by 50%

DURATION OF APPROVAL:

Initial authorization: 12 months, Continuation of therapy: 12 months

PRESCRIBER REQUIREMENTS:

None

AGE RESTRICTIONS:

18 years of age and older

QUANTITY:

max of 4 grams per day

PLACE OF ADMINISTRATION:

The recommendation is that oral medications in this policy will be for pharmacy benefit coverage and patient self-administered.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Oral

DRUG CLASS:

Antihyperlipidemics - Misc.

FDA-APPROVED USES:

VASCEPA is indicated:

- as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease.
- as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined

Drug and Biologic Coverage Criteria

LOVAZA is indicated:

- as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Limitations of Use: The effect of LOVAZA on the risk for pancreatitis has not been determined. The effect of LOVAZA on cardiovascular mortality and morbidity has not been determined

COMPENDIAL APPROVED OFF-LABELED USES:

None

APPENDIX

APPENDIX:

None

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

Lovaza (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving Lovaza and should continue this diet during treatment with Lovaza. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting Lovaza therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible, prior to consideration of triglyceride-lowering drug therapy. Limitations of Use The effect of Lovaza on the risk for pancreatitis has not been determined. The effect of Lovaza on cardiovascular mortality and morbidity has not been determined.

Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet and exercise regimen before receiving Vascepa and should continue this diet and exercise regimen with Vascepa. Attempts should be made to control any medical problems such as diabetes mellitus, hypothyroidism, and alcohol intake that may contribute to lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of TG-lowering drug therapy. Limitations of Use The effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. The effect of Vascepa on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

In REDUCE-IT, a randomized trial designed to evaluate the effect of fish oil therapy on CVD outcomes in patients with hypertriglyceridemia, a highly purified fish oil (icosapent ethyl) was effective. In this trial, over 8000 patients with elevated triglyceride levels (fasting 135 to 499 mg/DI [1.52 to 5.63 mmol/L]), on statin, and with either established CVD or diabetes plus other cardiovascular risk factors were randomly assigned to supplementation with icosapent ethyl 4 g daily or mineral oil. Icosapent ethyl reduced the risk of the primary combined CVD endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina (17.2 versus 22.0 percent, hazard ratio 0.75, 95% CI 0.68-0.83) after median follow-up of 4.9 years. From baseline to one year, the median triglyceride level decreased 18 percent in the treatment group and increased 2.2 percent in the control group, and LDL-C levels increased in both groups (treatment group 3.1 percent, control group 10.2 percent). At two years, C-reactive protein levels decreased by 13.9 percent in the treatment group and increased by 32.2 percent in the control group. A subsequently published prespecified analysis showed that the reduction occurred for both first and subsequent (i.e., total) ischemic events.

Limitations of the REDUCE-IT trial include concerns that mineral oil may have caused the increases in atherogenic lipoproteins and C-reactive proteins in the control group and thus did not function as

Molina Healthcare, Inc. confidential and proprietary © 2022

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

a true placebo. These adverse effects of mineral oil may have raised the risk of cardiovascular events in the control group and may partially account for the favorable risk reduction observed in the treatment group. If so, the true cardiovascular effect of icosapent ethyl may be less than observed in the trial. Another concern is that rates of new-onset atrial fibrillation were significantly higher in the treatment group (5.3 versus 3.9 percent). Further investigations to explain the mechanisms for the reduction in cardiovascular events with icosapent ethyl are warranted, considering that the modest reductions in fasting triglycerides are unlikely to account for the magnitude of benefit. It is also unknown whether other omega-3 preparations or doses would be similarly effective.

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of Omega-3 Fatty Acids are considered experimental/investigational and therefore will follow the Molina Healthcare, Inc. off-label policy.

OTHER SPECIAL CONSIDERATIONS:

None

CODING/BILLING INFORMATION

Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

HCP CODE	DESCRIPTION
NA	

AVAILABLE DOSAGE FORMS:

Lovaza capsules 1GM, Omega-3-acid Ethyl Esters Cap 1 GM, Vascepa capsule 0.5GM, Vascepa CAPS 1GM, Triko CAPS 1GM, Vascazen CAPS 1GM, Luvira CAPS 1.22GM, Icosapent Ethyl CAPS 1GM
Icosapent Ethyl CAPS 1GM

REFERENCES

1. Lovaza (omega-3-acid ethyl esters) [prescribing information]. Wixom, MI: Woodward Pharma Services LLC; February 2021.
2. Vascepa [package insert]. Bedminster, NJ: Arnarin Pharma Inc.; September 2021.
3. Omega-3 fatty acids [prescribing information]. Tempe, AZ: Century HealthCare Inc; July 2018.
4. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2021; 78:960.
5. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med* 2019; 380:11.
6. Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. *J Am Coll Cardiol* 2019; 73:2791.